Becton, Dickinson and Company (BDX)

US — Healthcare Sector
Peers: HAE  COO  ICUI  ANGO  WST  HOLX  XRAY  TFX  RMD  RGEN  ALC 

Automate Your Wheel Strategy on BDX

With Tiblio's Option Bot, you can configure your own wheel strategy including BDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BDX
  • Rev/Share 72.3516
  • Book/Share 87.5175
  • PB 2.0367
  • Debt/Equity 0.7634
  • CurrentRatio 1.1268
  • ROIC 0.0435

 

  • MktCap 51087697750.0
  • FreeCF/Share 8.9802
  • PFCF 19.725
  • PE 34.3186
  • Debt/Assets 0.3538
  • DivYield 0.0228
  • ROE 0.0586

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade BDX Citigroup Buy Neutral -- $185 May 22, 2025
Downgrade BDX Piper Sandler Overweight Neutral -- $185 May 2, 2025
Downgrade BDX Raymond James Outperform Market Perform -- -- May 2, 2025
Downgrade BDX Goldman Buy Neutral -- $192 May 2, 2025
Downgrade BDX William Blair Outperform Market Perform -- -- May 1, 2025
Downgrade BDX BofA Securities Buy Neutral -- $190 May 1, 2025
Downgrade BDX Wells Fargo Overweight Equal Weight -- -- May 1, 2025
Upgrade BDX Citigroup Neutral Buy $255 $275 Oct. 1, 2024

News

Becton, Dickinson and Company (BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day Transcript
BDX
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Becton, Dickinson and Company (NYSE:BDX ) Citi's 2025 Unplugged Medtech and Life Sciences Access Day November 27, 2025 8:45 AM ET Company Participants Tom Polen – Chairman, Chief Executive Officer and President Chris DelOrefice – Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch – Citi Joanne Wuensch We're live? Excellent.

Read More
image for news Becton, Dickinson and Company (BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day Transcript
My Best Dividend Aristocrats For March 2025
ABT, ADM, AFL, ALB, BDX, BEN, CHD, CHRW, CINF, CVX, ECL, ERIE, ES, ESS, GPC, HRL, MKC, NDSN, NEE, NOBL, O, PEP, PNR, PPG, ROP
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive

The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 43 months of tracking these strategies, one strategy is generating a CAGR superior to NOBL.

Read More
image for news My Best Dividend Aristocrats For March 2025
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
BDX
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
BDX
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term

About Becton, Dickinson and Company (BDX)

  • IPO Date 1973-02-21
  • Website https://www.bd.com
  • Industry Medical - Instruments & Supplies
  • CEO Thomas E. Polen Jr.
  • Employees 70000

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.